Locally Advanced Pancreatic Cancer Global Market Report 2025

Description

Locally advanced pancreatic cancer (LAPC) is a stage of pancreatic cancer in which the tumor remains confined to the pancreas and surrounding tissues but has not metastasized to distant organs. Due to its involvement with vital blood vessels or nearby structures, LAPC is typically not suitable for surgical removal.

The primary treatment options for locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy cancer cells or inhibit their growth. These therapies can be administered through various routes, including oral, injectable, and others, and are utilized in hospitals, specialty clinics, research institutes, and other healthcare settings.

The locally advanced pancreatic cancer market research report is one of a series of new reports from The Business Research Company that provides locally advanced pancreatic cancer market statistics, including the locally advanced pancreatic cancer industry's global market size, regional shares, competitors with a locally advanced pancreatic cancer market share, detailed locally advanced pancreatic cancer market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. This locally advanced pancreatic cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and enhanced supportive care options.

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing awareness of pancreatic cancer, advancements in chemotherapy regimens, the growing use of targeted therapies, a rising incidence of pancreatic cancer, the development of combination treatment protocols, and improved supportive care options. Major trends include advancements in immunotherapy, the development of targeted therapies, enhanced precision radiation techniques, improvements in diagnostic imaging, the adoption of minimally invasive surgical approaches, the integration of artificial intelligence in treatment planning, and progress in combination therapy strategies.

The rising consumption of tobacco is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco, derived from plant leaves, is commonly used in products such as cigarettes and cigars and contains nicotine, a highly addictive substance linked to severe health conditions such as cancer and heart disease. Several factors, including easy access, affordability, tobacco marketing, social acceptance in certain regions, and stress-related smoking, have driven the increase in tobacco use. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in January 2024, according to Global Action to End Smoking, a US-based non-profit organization dedicated to ending the smoking epidemic, approximately 62.9 million adults in the U.S. used tobacco in 2022, making it the fourth-highest globally and the highest in the Americas. Additionally, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with a higher prevalence among males (13.1%) compared to females (10.1%). Consequently, the increase in tobacco consumption is driving the expansion of the locally advanced pancreatic cancer market.

Leading companies in the locally advanced pancreatic cancer market are prioritizing the development of innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically designed to treat rare conditions affecting a limited population and are supported by regulatory incentives, including tax benefits and market exclusivity, to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its drug Elraglusib, a novel GSK-3B inhibitor, had received Orphan Drug Designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential form of locally advanced pancreatic cancer. This designation underscores its potential to address a critical gap in treating this severe cancer, particularly following promising Phase 2 trial results that demonstrated significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen AstraZeneca's oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and development and manufacturing capabilities, and accelerating the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company that focuses on developing targeted therapies for various types of cancer, including pancreatic cancer.

Major players in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co.

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in locally advanced pancreatic cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the locally advanced pancreatic cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Locally Advanced Pancreatic Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on locally advanced pancreatic cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for locally advanced pancreatic cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The locally advanced pancreatic cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; AbbVie Inc.; Bayer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34080

1. Executive Summary

2. Locally Advanced Pancreatic Cancer Market Characteristics

3. Locally Advanced Pancreatic Cancer Market Trends And Strategies

4. Locally Advanced Pancreatic Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Locally Advanced Pancreatic Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Locally Advanced Pancreatic Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Locally Advanced Pancreatic Cancer Market Growth Rate Analysis
5.4. Global Locally Advanced Pancreatic Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Locally Advanced Pancreatic Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Locally Advanced Pancreatic Cancer Total Addressable Market (TAM)

6. Locally Advanced Pancreatic Cancer Market Segmentation

6.1. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Radiation Therapy
Surgery
6.2. Global Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectables
Other Route Of Administrations
6.3. Global Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Specialty Clinics
Research Institutions
Other End-Users
6.4. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gemcitabine-based Chemotherapy
FOLFIRINOX Chemotherapy
6.5. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Cancer Vaccines
6.6. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy
Stereotactic Body Radiation Therapy (SBRT)
6.7. Global Locally Advanced Pancreatic Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pancreaticoduodenectomy (Whipple Procedure)
Distal Pancreatectomy
Total Pancreatectomy

7. Locally Advanced Pancreatic Cancer Market Regional And Country Analysis

7.1. Global Locally Advanced Pancreatic Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Locally Advanced Pancreatic Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Locally Advanced Pancreatic Cancer Market

8.1. Asia-Pacific Locally Advanced Pancreatic Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Locally Advanced Pancreatic Cancer Market

9.1. China Locally Advanced Pancreatic Cancer Market Overview
9.2. China Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Locally Advanced Pancreatic Cancer Market

10.1. India Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Locally Advanced Pancreatic Cancer Market

11.1. Japan Locally Advanced Pancreatic Cancer Market Overview
11.2. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Locally Advanced Pancreatic Cancer Market

12.1. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Locally Advanced Pancreatic Cancer Market

13.1. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Locally Advanced Pancreatic Cancer Market

14.1. South Korea Locally Advanced Pancreatic Cancer Market Overview
14.2. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Locally Advanced Pancreatic Cancer Market

15.1. Western Europe Locally Advanced Pancreatic Cancer Market Overview
15.2. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Locally Advanced Pancreatic Cancer Market

16.1. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Locally Advanced Pancreatic Cancer Market

17.1. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Locally Advanced Pancreatic Cancer Market

18.1. France Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Locally Advanced Pancreatic Cancer Market

19.1. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Locally Advanced Pancreatic Cancer Market

20.1. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Locally Advanced Pancreatic Cancer Market

21.1. Eastern Europe Locally Advanced Pancreatic Cancer Market Overview
21.2. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Locally Advanced Pancreatic Cancer Market

22.1. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Locally Advanced Pancreatic Cancer Market

23.1. North America Locally Advanced Pancreatic Cancer Market Overview
23.2. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Locally Advanced Pancreatic Cancer Market

24.1. USA Locally Advanced Pancreatic Cancer Market Overview
24.2. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Locally Advanced Pancreatic Cancer Market

25.1. Canada Locally Advanced Pancreatic Cancer Market Overview
25.2. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Locally Advanced Pancreatic Cancer Market

26.1. South America Locally Advanced Pancreatic Cancer Market Overview
26.2. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Locally Advanced Pancreatic Cancer Market

27.1. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Locally Advanced Pancreatic Cancer Market

28.1. Middle East Locally Advanced Pancreatic Cancer Market Overview
28.2. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Locally Advanced Pancreatic Cancer Market

29.1. Africa Locally Advanced Pancreatic Cancer Market Overview
29.2. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Locally Advanced Pancreatic Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Locally Advanced Pancreatic Cancer Market Competitive Landscape And Company Profiles

30.1. Locally Advanced Pancreatic Cancer Market Competitive Landscape
30.2. Locally Advanced Pancreatic Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Locally Advanced Pancreatic Cancer Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca plc
31.3. Abbott Laboratories
31.4. Novartis AG
31.5. GSK plc
31.6. Ipsen Biopharmaceuticals Inc.
31.7. Lupin Limited
31.8. NovoCure Limited
31.9. Theratechnologies Inc.
31.10. XBiotech
31.11. Prestige Biopharma
31.12. OSE Immunotherapeutics
31.13. Helix Biopharma Corporation
31.14. Fawn Incorporation
31.15. Eli Lilly and Co

32. Global Locally Advanced Pancreatic Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Locally Advanced Pancreatic Cancer Market

34. Recent Developments In The Locally Advanced Pancreatic Cancer Market

35. Locally Advanced Pancreatic Cancer Market High Potential Countries, Segments and Strategies

35.1 Locally Advanced Pancreatic Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Locally Advanced Pancreatic Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Locally Advanced Pancreatic Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer